Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

Myriad Genetic Laboratories

Status: Completed

Conditions: Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01954004

PROCEDE-1000

Details and patient eligibility

About

This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

Enrollment: 1,270 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
• Clinically localized (no evidence on clinical or imaging studies of advanced disease).
• No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
• Sufficient amount of tissue remains from biopsy to perform genomic testing.

Exclusion criteria

• Patients with a known history of hypogonadism